Alaunos Therapeutics, INC 8-K filings

Alaunos Therapeutics announced new preclinical statistical analysis of ALN1003 in mice, showing reduced liver weight adjusted for body fat, consistent with other positive liver-related biomarkers.

Alaunos Therapeutics announced integrated preclinical results for ALN1003, an investigational oral drug for obesity and metabolic disorders, showing positive effects in mouse studies.

Alaunos Therapeutics announced updated preclinical data for its investigational oral metabolic therapeutic candidate, ALN1003, showing positive effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity mouse models.

Alaunos Therapeutics has been notified by Nasdaq of non-compliance with minimum stockholders' equity requirements.

Alaunos Therapeutics announced positive preclinical proof-of-concept data for its lead small-molecule drug candidate, ALN1003, for obesity and metabolic disorders.

Alaunos Therapeutics announced the termination of its financial advisor, adopted new bylaws, and reported encouraging preclinical data for its obesity program, while also highlighting an urgent need for additional financing.

Alaunos Therapeutics, Inc. has entered into a Settlement and Release Agreement with MD Anderson Cancer Center to resolve outstanding invoice disputes totaling $285,055.68.

Alaunos Therapeutics, Inc. has successfully regained compliance with Nasdaq's continued listing requirements, resolving a prior deficiency related to stockholders' equity.

Alaunos Therapeutics, Inc. announced the resignation of Melinda Lackey as Legal and Administrative Officer and Corporate Secretary, effective August 15, 2025, with the company stating her departure was not due to any disagreements.

Alaunos Therapeutics, Inc. announced the appointment of Michael A. Jerman as an independent director, effective July 15, 2025, filling a vacancy and taking on key committee roles including chair of the Audit Committee.

Alaunos Therapeutics, Inc. stockholders approved key proposals at its Annual Meeting, including a significant increase in authorized common stock, a potential reverse stock split, and an expansion of its equity incentive plan.

Alaunos Therapeutics, Inc. announced the immediate resignation of its CEO and director, Dale Curtis Hogue, Jr., the appointment of Holger Weis as the new CEO, and a notice of non-compliance with Nasdaq's audit committee requirements.

Alaunos Therapeutics, Inc. has completed a registered direct offering, raising approximately $2 million by issuing common stock and pre-funded warrants for general corporate purposes.

Alaunos Therapeutics, Inc. has completed a private offering of Series A-2 Convertible Preferred Stock, raising $850,000 to bolster its financial position.

Alaunos Therapeutics, Inc. has amended its common stock purchase warrant with Mast Hill Fund, L.P., establishing a $0.57 per share floor price for certain adjustments and removing provisions that would increase the number of shares issuable upon exercise.

Alaunos Therapeutics, Inc. has entered into an equity purchase agreement with Mast Hill Fund, L.P. for up to $25 million in common stock over 24 months, alongside a warrant for 79,900 shares, providing flexible access to capital.

Robert Hofmeister, Ph.D., resigned from the Alaunos Therapeutics, Inc. Board of Directors effective April 15, 2025.

Alaunos Therapeutics' Board of Directors elected to receive equity compensation instead of cash for deferred service fees, resulting in the issuance of common stock and stock options.

Alaunos Therapeutics entered into a subscription agreement with Watermill Asset Management, issuing Series A-1 Convertible Preferred Stock for $500,000 in a private offering.

Alaunos Therapeutics received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Alaunos Therapeutics has terminated its license agreement with Precigen, shifting its focus to an internally developed oral obesity program and exploring strategic alternatives.

Alaunos Therapeutics has completed a 1-for-10 reverse stock split, effective July 17, 2024, to increase its share price and maintain Nasdaq listing compliance.

Alaunos Therapeutics has finalized a 1-for-10 reverse stock split, effective July 17, 2024, to increase the per-share price of its common stock.

Alaunos Therapeutics has completed a 1-for-10 reverse stock split, effective July 17, 2024, to consolidate its shares and adjust its trading price.

Alaunos Therapeutics will implement a 1-for-10 reverse stock split effective July 17, 2024, to consolidate its shares.

Alaunos Therapeutics has dismissed RSM US LLP as its independent auditor and appointed Cherry Bekaert LLP, effective June 19, 2024.

Alaunos Therapeutics' stockholders approved an increase in authorized shares to 50 million and a potential reverse stock split at the company's annual meeting on June 6, 2024.

Alaunos Therapeutics has announced the resignation of its Vice President of Finance and the appointment of a new finance lead through a consulting agreement.

Alaunos Therapeutics has been notified by Nasdaq that it has regained compliance with the minimum $1.00 bid price requirement and will be subject to a mandatory panel monitor for one year.

Alaunos Therapeutics has completed a 1-for-15 reverse stock split, effective January 31, 2024, to consolidate its shares.